| Trial ID: | L1736 |
| Source ID: | NCT00098020
|
| Associated Drug: |
Isotretinoin
|
| Title: |
Podocyte Retinoids
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT00098020/results
|
| Conditions: |
Collapsing Glomerulopathy|Glomerulosclerosis, Focal Segmental
|
| Interventions: |
DRUG: Isotretinoin
|
| Outcome Measures: |
Primary: Change in Proteinuria at Week 24 From Baseline, Change of proteinuria at Week 24 compared to the baseline using protein/creatinine ratio (PCR), Baseline and Week 24 | Secondary: Number of Patients Who Are in Complete Remission (CR) or Partial Remission (PR) at 6 Months or at the End of One Year., Based on 24hour proteinuria, response outcomes are defined as CR (complete remission): \<0.3 g/g PR (partial remission): 50% fall from baseline and \<2.0 g/g, End of one year from baseline
|
| Sponsor/Collaborators: |
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
|
| Gender: |
ALL
|
| Age: |
CHILD, ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
12
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2004-11-26
|
| Completion Date: |
2016-06-27
|
| Results First Posted: |
2017-12-13
|
| Last Update Posted: |
2017-12-13
|
| Locations: |
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, 20892, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT00098020
|
